Introgen Obtains Exclusive US Patent for Development of Adenoviral Vector Based Gene Therapies (Business Wire via Yahoo! Finance)
Introgen Obtains Exclusive US Patent for Development of Adenoviral Vector Based Gene Therapies (Business Wire via Yahoo! Finance)
AUSTIN, Texas—-Introgen Therapeutics, Inc. announced today that a patent has been awarded titled “Diminishing Viral Gene Expression by Promoter Replacement” by the U.S. Patent and Trademark Office focusing on adenoviral vector development, which is the most commercially important type of viral vector used in the field of gene therapy.